Cookies allow us to understand how you use this site and improve your experience. Our detailed Cookie Policy can be found here. By continuing to use this website you accept our use of cookies.
To manage the use of cookies click .
Mandatory cookies help make this website usable by enabling basic functions like page navigation and access to secure areas of the website. Our website cannot function properly without these cookies.
Statistic cookies help us understand how visitors interact with this website, for example seeing which pages are most popular. This information is collected anonymously and helps us improve the site by making the most sought after information easy to find.
Marketing cookies are used to track visitors across websites allowing the display of ads that are relevant and engaging for the visitor. Whilst we do not display any advertising on the WJC website, allowing marketing cooking may allow other sites to see that you have visited our site.
Josh Wolfe is a co-founder and the managing partner at Lux Capital, a venture capital fund that invests in deep technology and frontier science. He serves on the boards of Aera Therapeutics, Cajal Neuroscience, Eikon Therapeutics, Impulse Labs, Kallyope, Osmo, and Variant Bio, and led investments in Anduril, Planet, Echodyne, Hadrian, and Resilience. A Westinghouse semi-finalist and published scientist, Josh began his career at Salomon Smith Barney and Merrill Lynch. He edits the Forbes/Wolfe Emerging Tech Report and has advised the White House and Congress on emerging technologies. Josh is also a term member of the Council on Foreign Relations, Trustee of the Santa Fe Institute, and Chairman of Coney Island Prep. He holds a B.S. in Economics and Finance from Cornell.
Sign up to receive our weekly newsletter The latest from the Jewish world